Tumor Biology

, Volume 36, Issue 9, pp 6805–6811 | Cite as

miR-30 overexpression promotes glioma stem cells by regulating Jak/STAT3 signaling pathway

  • Shusheng Che
  • Tingting Sun
  • Jianpeng Wang
  • Yingbin Jiao
  • Chao Wang
  • Qinghai Meng
  • Weiguo Qi
  • Zhiyong YanEmail author
Research Article


Malignant glioma is the most common intracranial tumor with poor prognosis. It is well believed that glioma stem cells (GSCs) are responsible for the initiation and progression of glioma. Janus kinase/signal transducer and activator of transcription (Jak/STAT3) pathway plays a key role in the functions of GSCs. However, the regulatory mechanism of Jak/STAT3 pathway has not been completely elucidated. This study employed multidisciplinary approaches to investigate the upstream regulators of Jak/STAT3 signaling in GSCs. miR-30 was found to be overexpressed in the GSCs derived from U-87 MG and primary glioma cells, compared with non-stem-cell-like glioma cells and normal cells. Downregulation of miR-30 was able to suppress Jak/STAT3 pathway and reduce the tumorigenecity of GSCs. miR-30 decreased the expression of suppressor of cytokine signaling 3 (SOCS3) expression by targeting 3′UTR of its mRNA. The silencing of SOCS3 abolished the effect of miR-30 downregulation on GSCs. Collectively, there is a regulatory pathway consisting of miR-30, SOCS3, and Jak/STAT3 in GSCs, and targeting this pathway may be a promising strategy to treat glioma.


miR-30 SOCS3 Jak/STAT3 Glioma GSC 

Supplementary material

13277_2015_3400_Fig5_ESM.jpg (148 kb)

(JPEG 148 kb)

13277_2015_3400_MOESM1_ESM.pptx (93 kb)
ESM 2 (PPTX 93 kb)
13277_2015_3400_MOESM2_ESM.docx (28 kb)
ESM 3 (DOCX 28 kb)


  1. 1.
    Ashizawa T, Miyata H, Iizuka A, Komiyama M, Oshita C, Kume A, et al. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma. Int J Oncol. 2013;43:219–27.PubMedGoogle Scholar
  2. 2.
    Bexell D, Svensson A, Bengzon J. Stem cell-based therapy for malignant glioma. Cancer Treat Rev. 2013;39:358–65.CrossRefPubMedGoogle Scholar
  3. 3.
    Brower JV, Clark PA, Lyon W, Kuo JS. MicroRNAs in cancer: glioblastoma and glioblastoma cancer stem cells. Neurochem Int. 2014;77:68–77.Google Scholar
  4. 4.
    Cao Q, Li YY, He WF, Zhang ZZ, Zhou Q, Liu X, et al. Interplay between microRNAs and the STAT3 signaling pathway in human cancers. Physiol Genomics. 2013;45:1206–14.CrossRefPubMedGoogle Scholar
  5. 5.
    Cao Y, Lathia JD, Eyler CE, Wu Q, Li Z, Wang H, et al. Erythropoietin receptor signaling through STAT3 is required for glioma stem cell maintenance. Genes Cancer. 2010;1:50–61.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Cardoso AL, Guedes JR, Pereira de Almeida L, Pedroso de Lima MC. miR-155 modulates microglia-mediated immune response by down-regulating SOCS-1 and promoting cytokine and nitric oxide production. Immunology. 2012;135:73–88.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Collins AS, McCoy CE, Lloyd AT, O’Farrelly C, Stevenson NJ. miR-19a: an effective regulator of SOCS3 and enhancer of JAK-STAT signalling. PLoS ONE. 2013;8:e69090.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Cui X, Liu J, Bai L, Tian J, Zhu J. Interleukin-6 induces malignant transformation of rat mesenchymal stem cells in association with enhanced signaling of signal transducer and activator of transcription 3. Cancer Sci. 2014;105:64–71.CrossRefPubMedGoogle Scholar
  9. 9.
    Ehrmann J, Strakova N, Vrzalikova K, Hezova R, Kolar Z. Expression of STATs and their inhibitors SOCS and PIAS in brain tumors. In vitro and in vivo study. Neoplasma. 2008;55:482–7.PubMedGoogle Scholar
  10. 10.
    Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21:2683–710.CrossRefPubMedGoogle Scholar
  11. 11.
    Garner JM, Fan M, Yang CH, Du Z, Sims M, Davidoff AM, et al. Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor kappaB signaling in glioblastoma cancer stem cells regulates the Notch pathway. J Biol Chem. 2013;288:26167–76.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Haftchenary S, Luchman HA, Jouk AO, Veloso AJ, Page BD, Cheng XR, et al. Potent targeting of the STAT3 protein in brain cancer stem cells: a promising route for treating glioblastoma. ACS Med Chem Lett. 2013;4:1102–7.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell. 2013;23:839–52.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Li GH, Wei H, Lv SQ, Ji H, Wang DL. Knockdown of STAT3 expression by RNAi suppresses growth and induces apoptosis and differentiation in glioblastoma stem cells. Int J Oncol. 2010;37:103–10.PubMedGoogle Scholar
  15. 15.
    Martini M, Pallini R, Luongo G, Cenci T, Lucantoni C, Larocca LM. Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. Int J Cancer. 2008;123:2955–60.CrossRefPubMedGoogle Scholar
  16. 16.
    Moffatt CE, Lamont RJ. Porphyromonas gingivalis induction of microRNA-203 expression controls suppressor of cytokine signaling 3 in gingival epithelial cells. Infect Immun. 2011;79:2632–7.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Natsume A, Kinjo S, Yuki K, Kato T, Ohno M, Motomura K, et al. Glioma-initiating cells and molecular pathology: implications for therapy. Brain Tumor Pathol. 2011;28:1–12.CrossRefPubMedGoogle Scholar
  18. 18.
    Quintavalle C, Donnarumma E, Iaboni M, Roscigno G, Garofalo M, Romano G, et al. Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells. Oncogene. 2013;32:4001–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.CrossRefPubMedGoogle Scholar
  20. 20.
    Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821–8.PubMedGoogle Scholar
  21. 21.
    Starr R, Hilton DJ. SOCS: suppressors of cytokine signalling. Int J Biochem Cell Biol. 1998;30:1081–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signalling. Nature. 1997;387:917–21.CrossRefPubMedGoogle Scholar
  23. 23.
    Wu N, Xiao L, Zhao X, Zhao J, Wang J, Wang F, et al. miR-125b regulates the proliferation of glioblastoma stem cells by targeting E2F2. FEBS Lett. 2012;586:3831–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Zhou M, Wang H, Zhou K, Luo X, Pan X, Shi B, et al. A novel EGFR isoform confers increased invasiveness to cancer cells. Cancer Res. 2013;73:7056–67.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Shusheng Che
    • 1
  • Tingting Sun
    • 2
  • Jianpeng Wang
    • 1
  • Yingbin Jiao
    • 1
  • Chao Wang
    • 1
  • Qinghai Meng
    • 1
  • Weiguo Qi
    • 1
  • Zhiyong Yan
    • 1
    Email author
  1. 1.Department of Neurosurgerythe Affiliated Hospital of Qingdao UniversityQingdaoChina
  2. 2.Intensive Care UnitQingdao Municipal HospitalQingdaoChina

Personalised recommendations